Literature DB >> 32460180

Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.

Ashwathy Susan Mathew1, Eshetu G Atenafu2, Dawn Owen3, Chris Maurino3, Anthony Brade1, James Brierley1, Robert Dinniwell1, John Kim1, Charles Cho1, Jolie Ringash1, Rebecca Wong1, Kyle Cuneo3, Mary Feng3, Theodore S Lawrence3, Laura A Dawson4.   

Abstract

BACKGROUND: Stereotactic Body Radiation Therapy (SBRT) is a non-invasive ablative treatment for hepatocellular carcinoma (HCC). This report aimed to address the limited availability of long-term outcomes after SBRT for HCC from North America.
METHODS: Localized HCC patients without vascular invasion, who were ineligible for other liver-directed therapies and treated with SBRT at the University of Toronto or University of Michigan, were pooled to determine overall survival (OS), cumulative recurrence rates, and ≥ grade-3 toxicity. Multivariable analysis determined factors affecting OS and local recurrence rates.
RESULTS: In 297 patients with 436 HCCs (42% > 3 cm), one-, three- and five-year OS was 77·3%, 39·0% and 24·1%, respectively. On Cox proportional hazards regression analysis, liver transplant after SBRT, Child-Pugh A liver function, alpha-fetoprotein ≤ 10 ng/ml, and Eastern Co-operative Oncology Group performance status 0 significantly improved OS (hazard ratio [HR] = 0·06, 95% confidence interval [CI- 0·02-0·25; p<0·001; HR = 0·42, 95% CI = 0·29-0·60, p<0·001; HR = 0·61, 95% CI- 0·44-0·83; p=0·002 and HR = 0·71, 95% CI = 0·51-0·97, p=0·034, respectively). Cumulative local recurrence was 6·3% (95% CI = 0.03-0.09) and 13·3% (95% CI = 0.06-0.21) at one and three years, respectively. Using Cox regression modelling, local control was significantly higher using breath-hold motion management and in HCC smaller than 3 cm (HR = 0.52, 95% CI = 0.58-0.98; p=0.042 and HR = 0.53, 95% CI = 0.26-0.98; p=0.042, respectively). Worsening of Child-Pugh score by ≥2 points three months after SBRT was seen in 15.9%.
CONCLUSIONS: SBRT confers high local control and long-term survival in a substantial proportion of HCC patients unsuitable for, or refractory to standard loco-regional treatments. Liver transplant should be considered if appropriate downsizing occurs after SBRT. Crown
Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Hepatocellular carcinoma; Liver; Radiation; Stereotactic

Mesh:

Year:  2020        PMID: 32460180      PMCID: PMC7340168          DOI: 10.1016/j.ejca.2020.04.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  26 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Michael Velec; Carol R Haddad; Tim Craig; Lisa Wang; Patricia Lindsay; James Brierley; Anthony Brade; Jolie Ringash; Rebecca Wong; John Kim; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-01       Impact factor: 7.038

4.  Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma.

Authors:  Shaelyn Culleton; Haiyan Jiang; Carol R Haddad; John Kim; Jim Brierley; Anthony Brade; Jolie Ringash; Laura A Dawson
Journal:  Radiother Oncol       Date:  2014-06-03       Impact factor: 6.280

5.  Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial.

Authors:  Zhen-Wei Peng; Yao-Jun Zhang; Hui-Hong Liang; Xiao-Jun Lin; Rong-Ping Guo; Min-Shan Chen
Journal:  Radiology       Date:  2011-12-12       Impact factor: 11.105

6.  Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.

Authors:  Atsuya Takeda; Naoko Sanuki; Yuichiro Tsurugai; Shogo Iwabuchi; Kotaro Matsunaga; Hirotoshi Ebinuma; Kento Imajo; Yousuke Aoki; Hidetsugu Saito; Etsuo Kunieda
Journal:  Cancer       Date:  2016-04-08       Impact factor: 6.860

7.  Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.

Authors:  Naoko Sanuki; Atsuya Takeda; Yohei Oku; Tomikazu Mizuno; Yosuke Aoki; Takahisa Eriguchi; Shogo Iwabuchi; Etsuo Kunieda
Journal:  Acta Oncol       Date:  2013-08-21       Impact factor: 4.089

8.  Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.

Authors:  Mary Feng; Krithika Suresh; Matthew J Schipper; Latifa Bazzi; Edgar Ben-Josef; Martha M Matuszak; Neehar D Parikh; Theodore H Welling; Daniel Normolle; Randall K Ten Haken; Theodore S Lawrence
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

9.  Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

Authors:  Shuichiro Shiina; Ryosuke Tateishi; Toru Arano; Koji Uchino; Kenichiro Enooku; Hayato Nakagawa; Yoshinari Asaoka; Takahisa Sato; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  Am J Gastroenterol       Date:  2011-12-13       Impact factor: 10.864

Review 10.  Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis.

Authors:  Chenyang Duan; Mengying Liu; Zhuohang Zhang; Kuansheng Ma; Ping Bie
Journal:  World J Surg Oncol       Date:  2013-08-13       Impact factor: 2.754

View more
  9 in total

Review 1.  Frontiers of therapy for hepatocellular carcinoma.

Authors:  Michael Heller; Neehar D Parikh; Nicholas Fidelman; Dawn Owen
Journal:  Abdom Radiol (NY)       Date:  2021-04-10

Review 2.  Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.

Authors:  Shirley Lewis; Laura Dawson; Aisling Barry; Teodor Stanescu; Issa Mohamad; Ali Hosni
Journal:  JHEP Rep       Date:  2022-05-14

3.  LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.

Authors:  Mishal Mendiratta-Lala; Anum Aslam; Katherine E Maturen; Maria Westerhoff; Chris Maurino; Neehar D Parikh; Yilun Sun; Christopher J Sonnenday; Erica B Stein; Kimberly L Shampain; Ravi K Kaza; Kyle Cuneo; William Masch; Richard Kinh Gian Do; Theodore S Lawrence; Dawn Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-10-10       Impact factor: 8.013

4.  The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.

Authors:  William C Jackson; Holly E Hartman; Laila A Gharzai; Christopher Maurino; David M Karnak; Mishal Mendiratta-Lala; Neehar D Parikh; Charles S Mayo; Randall K Ten Haken; Matthew J Schipper; Kyle C Cuneo; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-04-18       Impact factor: 8.013

Review 5.  Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination.

Authors:  Luis A Pérez-Romasanta; Elisabet González-Del Portillo; Ana Rodríguez-Gutiérrez; Ángela Matías-Pérez
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 6.  Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.

Authors:  Valerie J W Tong; Vishal G Shelat; Yew Kuo Chao
Journal:  J Clin Transl Res       Date:  2021-11-06

7.  Neutrophil-to-lymphocyte ratio as a prognostic predictor for patients with cancer treated with stereotactic body radiation therapy: A meta-analysis.

Authors:  Yipin Yu; Duoting Tan; Can Liao; Pei Yang; Zhixi Hu; Hao Liang
Journal:  Mol Clin Oncol       Date:  2022-03-17

8.  Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety.

Authors:  Isaure Roquette; Emilie Bogart; Thomas Lacornerie; Massih Ningarhari; Jean-Emmanuel Bibault; Marie-Cecile Le Deley; Eric F Lartigau; David Pasquier; Xavier Mirabel
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

9.  Life Beyond COVID: Pay Attention to Viruses.

Authors:  Paul M Harari; Paul F Lambert
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-10-01       Impact factor: 7.038

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.